Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 6, 2014

View Archived Issues

Kyowa Hakko Kirin reports milestones of fourth quarter 2013

Shionogi initiates phase II study of cancer peptide vaccine in-licensed from OncoTherapy Science

Ablynx forms cancer immunotherapy discovery collaboration with Merck & Co.

Furiex Pharmaceuticals reports topline results from two phase III trials of eluxadoline

Critical Path Institute awarded grant to accelerate tuberculosis drug development

Domain Therapeutics collaborates with Xoma on G protein-coupled receptors

First patient dosed in phase I/II trial of STP-206 for necrotizing enterocolitis in neonates

New benzothiazole derivatives synthesized by Bristol-Myers Squibb for dyslipidemia

Cell-in-a-Box technology to be used by Medical Marijuana Sciences to develop cancer treatments

PSMA-ADC treatment leads to CTC and PSA reductions in patients with metastatic CRPC

Preliminary phase I results show safety of DC-Ad-GMCAIX treatment in patients with RCC

Ipsen to seek approval for Dysport Next Generation ready-to-use liquid toxin A

AbbVie reports progress of fourth quarter 2013

Structure-based development of novel inhibitors of MERS-CoV

Favipiravir demonstrates activity against Rift Valley fever virus

Development of a new class of semisynthetic antituberculosis agents to overcome drug resistance

Researchers at Blueprint Medicines disclose new FGFR-4 inhibitors

Shionogi and Hokkaido University claim new BACE1 inhibitors for AD

BARDA awards contract to The Medicines Company/Rempex for Carbavance

New LTA-4 hydrolase inhibitors disclosed by Boehringer Ingelheim

Trevena begins development program for pain treatment candidate

Alliance between Regulus and Sanofi renewed to focus on orphan disease and oncology targets

Ability Pharmaceuticals gains approval for phase I/Ib trial of anticancer drug in Spain

Zosano Pharma and Novo Nordisk enter agreement to develop transdermal formulation of semaglutide

Omeros gains FDA fast track designation for OMS-824 in Huntington's disease

Regenera to conduct phase II trial of RPh-201 in treatment of ischemic optic neuropathy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...